841 studies found for:    Open Studies | "Carcinoma, Non-Small-Cell Lung"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Non-Small-Cell Lung"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
2 Recruiting Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer
Interventions: Drug: CC-223, erlotinib;   Drug: CC-223, oral azacitidine
3 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
Intervention:
4 Not yet recruiting Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Conditions: Carcinoma, Non-Small Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Pazopanib
5 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
6 Recruiting Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
Conditions: Cachexia;   Fatigue;   Pulmonary Complications;   Radiation Toxicity;   Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Behavioral: exercise intervention;   Procedure: pulmonary complications management/prevention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
7 Recruiting Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Lenalidomide
8 Recruiting Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Sym004 plus Platinum-Doublet Chemotherapy
9 Recruiting Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Tecemotide;   Drug: Placebo;   Drug: Cyclophosphamide (CPA);   Drug: Saline (sodium chloride)
10 Recruiting Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Oshadi D and Oshadi R;   Drug: Docetaxel
11 Recruiting Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: HyperAcute®-Lung Immunotherapy;   Drug: Gemcitabine;   Drug: Pemetrexed
12 Recruiting Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
Conditions: Non-small Cell Lung Cancer Stage I;   Non-small Cell Lung Cancer Stage II;   Non-small Cell Lung Cancer Stage IIIA
Intervention:
13 Unknown  Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Endostatins;   Drug: Docetaxel
14 Recruiting Gene Mutations in Non-Small Cell Lung Cancer Cells
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
15 Recruiting Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System
Condition: Non-Small Cell Lung Carcinoma
Intervention: Radiation: Radiotherapy (Fractionated stereotactic body radiation)
16 Recruiting Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel;   Drug: Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
17 Recruiting Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
Condition: Carcinoma, Non-Small Cell Lung
Intervention: Other: Radiation Therapy and EGFR-TKI target therapy
18 Recruiting Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Condition: Carcinoma, Non-small Cell Lung
Intervention: Drug: Aprepitant
19 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD6244;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
20 Recruiting Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Ruxolitinib;   Drug: Placebo;   Drug: Pemetrexed;   Drug: Cisplatin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years